The outcome of rituximab in treating steroid dependent nephrotic syndrome.

References

1. 1.↵
   1. Lombel RM,
   2. Gipson DS,
   3. Hodson EM.

   Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 2013; 28: 415–426.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Maxted AP,
   2. Dalrymple RA,
   3. Chisholm D,
   4. McColl J,
   5. Tse Y,
   6. Christian MT, et al.

   Low-dose rituximab is no less effective for nephrotic syndrome measured by 12-month outcome. Pediatr Nephrol 2019; 34: 855–863.

   OpenUrl
3. 3.↵
   1. Trautmann A,
   2. Vivarelli M,
   3. Samuel S,
   4. Gipson D,
   5. Sinha A,
   6. Schaefer F, et al.

   IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2020; 35: 1529–1561.

   OpenUrlPubMed
4. 4.↵
   1. Xiao JP,
   2. Wang J,
   3. Yuan L,
   4. Wang DG.

   The efficacy of rituximab in the treatment of refractory nephrotic syndrome: a meta-analysis. Int Urol Nephrol 2020; 52: 1093–1101.

   OpenUrl
5. 5.↵
   1. Kemper MJ,
   2. Valentin L,
   3. van Husen M.

   Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options. Pediatr Nephrol 2018; 33: 1641–1649.

   OpenUrl
6. 6.↵
   1. Delbet JD,
   2. Leclerc G,
   3. Ulinski T.

   Idiopathic nephrotic syndrome and rituximab: may we predict circulating B lymphocytes recovery? Pediatr Nephrol 2019; 34: 529–532.

   OpenUrl
7. 7.↵
   1. Ravani P,
   2. Rossi R,
   3. Bonanni A,
   4. Quinn RR,
   5. Sica F,
   6. Bodria M, et al.

   Rituximab in children with steroid-dependent nephrotic ayndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 2015; 26: 2259–2266.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Ravani P,
   2. Magnasco A,
   3. Edefonti A,
   4. Murer L,
   5. Rossi R,
   6. Ghio L, et al.

   Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 2011; 6: 1308–1315.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Iijima K,
   2. Sako M,
   3. Kamei K,
   4. Nozu K.

   Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials. Pediatr Nephrol 2018; 33: 1449–1455.

   OpenUrl
10. 10.↵
    1. Benz K,
    2. Dötsch J,
    3. Rascher W,
    4. Stachel D.

    Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 2004; 19: 794–797.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Iijima K,
    2. Sako M,
    3. Nozu K.

    Rituximab treatment for nephrotic syndrome in children. Curr Pediatr Rep 2015; 3: 71–77.

    OpenUrl
12. 12.↵
    1. Ravani P,
    2. Lugani F,
    3. Pisani I,
    4. Bodria M,
    5. Piaggio G,
    6. Bartolomeo D, et al.

    Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study. Pediatr Nephrol 2020; 35: 1437–1444.

    OpenUrlPubMed
13. 13.↵
    1. Girişgen İ,
    2. Yüksel S,
    3. Pekal Y.

    Rituximab experience in children with nephrotic syndrome: what have we observed differently. Turk Pediatri Ars 2020; 55: 60–66.

    OpenUrl
14. 14.↵
    1. Vanikar A.

    IgM nephropathy; can we still ignore it. J Nephropathol 2013; 2: 98–103.

    OpenUrl
15. 15.↵
    1. Hogan J,
    2. Dossier C,
    3. Kwon T,
    4. Macher MA,
    5. Maisin A,
    6. Couderc A, et al.

    Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2019; 34: 253–259.

    OpenUrl
16. 16.↵
    1. Takahashi T,
    2. Okamoto T,
    3. Sato Y,
    4. Yamazaki T,
    5. Hayashi A,
    6. Aoyagi H, et al.

    Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study. Pediatr Nephrol 2019; 34: 87–96.

    OpenUrl